Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
February 24, 2024 at 14:20 PM EST
Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody evaluation/option agreement with Gilead Sciences.
